Full-year 2025 guidance: non-GAAP operating margin -- Expected between 23.5% and 24.5%, reflecting increases in sales and ...

One clinical-stage biotech is defying gravity—here’s why its record-breaking run is catching institutional attention.

Net Income -- $7.6 million, down from $9.3 million. Net income attributable to Karat ( KRT +1.51%) was $7.3 million, or $0.36 ...

Q4 2025 guidance -- Projected total revenue of $371 million to $377 million; subscription revenue of $258 million to $261 ...

Relacorilant NDA updates -- FDA PDUFA date set for Dec. 30, 2025 (hypercortisolism); platinum-resistant ovarian cancer PDUFA ...

Total Revenue -- $21.2 million for the third quarter of 2025, up 16%, driven by MRI compatible IV infusion pump and ...

Upcoming product launches -- AMP-007 inhalation on track for mid-2026 launch targeting a $1.5 billion market; generic ...

Total production -- Reached a quarterly record of approximately 1.62 million BOEs per day, reflecting a 19% increase, or ...

PN-943 (IBD Program) -- Oral, gut-restricted alpha-4-beta-7 integrin antagonist demonstrated greater than threefold improved ...

gTLD process -- The ICANN 2026 round of new generic Top-Level Domains is intended to start in Q2 2026, with no future ...

Join us as we dissect Lululemon's stock performance and explore whether it can reclaim its former glory in the competitive ...

Walmart's results showcase the nuances of purchasing decisions. Often, consumers don't eliminate a purchase, but shift the ...